Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum

NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
March 08, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures

OV350 is the first reported compound that directly binds to and activates the KCC2 co-transporter, a target implicated in neuronal excitation, including epilepsiesTwo preclinical seizure models...
February 28, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
February 08, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

Recognized epileptologist and medical affairs leader, Manoj Malhotra, M.D., joins as Chief Medical Officer Drug discovery and development scientist and soticlestat co-inventor, Toshiya Nishi, D.V.M.,...
January 05, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
December 02, 2022 10:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

Preclinical data demonstrate potential efficacy and safety of OV329 at low, chronic dosing, suggesting an improved profile compared to other GABA-aminotransferase inhibitors Data from the NIH/NINDs...
November 08, 2022 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

Ovid intends to initiate a Phase 1 study in healthy volunteers in Q4 2022, following the FDA clearance of an Investigational New Drug (IND) application for OV329, its GABA-aminotransferase...
September 27, 2022 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
September 07, 2022 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
August 09, 2022 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the second half of 2022 Presented preclinical data...